source
- AI chemistry agent gives wrong answer after handling malformed data, highlighting safety concerns in drug researchAn AI chemistry agent called ChemAgent was tasked with checking whether a molecule had a known hepatobiliary side effect. The agent supplied the molecular structure in an invalid format to a speci…
- AstraZeneca puts $2 billion into Summit Therapeutics and partners to test ivonescimab with its oncology pipelineAstraZeneca announced a $2 billion equity investment in Summit Therapeutics, acquiring roughly 109,000 shares of convertible preferred stock. The deal will give AstraZeneca about a 12% stake in Sum…